Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Apraglutide - Ironwood Pharmaceuticals

Next Previous
Drug Profile

Apraglutide - Ironwood Pharmaceuticals

Alternative Names: FE 203799; GLP2 analouge; Glucagon-like peptide-2 receptor agonist - Ferring Pharmaceuticals/Ironwood Pharmaceuticals

Latest Information Update: 20 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ferring Pharmaceuticals
  • Developer Ironwood Pharmaceuticals; Therachon
  • Class Glucagon-like peptides
  • Mechanism of Action Glucagon-like peptide 2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease; Short bowel syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Short bowel syndrome
  • Phase I Unspecified
  • No development reported Gastrointestinal disorders
  • Discontinued Graft-versus-host disease

Most Recent Events

  • 07 Aug 2025 Efficacy data from the phase III STARS Extend trial in Short bowel syndrome released by
  • 07 Aug 2025 Ironwood Pharmaceuticals announces intention to align with the FDA, in the fourth quarter of 2025
  • 07 Aug 2025 Ironwood Pharmaceuticals plans a confirmatory phase III trial for Short bowel syndrome in USA (SC), in the first half of 2026

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top